BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Teva Pharmaceutical Industries Limited (TEVA) Asks FDA Not to Approve Biogen Idec, Inc. (Massachusetts) (BIIB) MS Drugs


1/10/2013 7:29:19 AM

Teva Pharmaceutical Industries Ltd, which makes the market-leading multiple sclerosis drug Copaxone, has filed a petition with the U.S. Food and Drug Administration that could, if granted, delay entry to the market of a rival drug developed by Biogen Idec Inc. Teva's petition asks that the FDA not approve any new multiple sclerosis drug until its safety has been evaluated by a panel of outside advisors, and said it had uncovered "troubling information" on a publicly accessible website about the safety of Biogen's drug, BG-12. Israel-based Teva said the information showed that kidney changes were observed after repeated administration of BG-12 in mice, rats, dogs and monkeys. The company suggested that as a result, "there is a substantial probability the risk is applicable to humans as well." Biogen spokeswoman Kate Niazi-Sai, echoing comments made by company chief executive, George Scangos, at the J.P. Morgan Healthcare Conference earlier this week, said the company is "confident" in BG-12's safety data. Niazi-Sai said the incidence of kidney problems was similar between patients taking BG-12 and those taking a placebo, she said. A late-stage clinical trial showed that 21 percent of patients taking the placebo experienced kidney problems, compared with 22 percent of patients taking BG-12 twice a day and 25 percent of patients taking BG-12 three times a day. Teva asked the FDA not to approve any new MS drug unless or until it has convened a panel of outside advisors and listened to the panel's recommendations. And it said its motives were to protect patients. "Teva filed the petition, on behalf of the more than 300,000 patients with relapsing remitting multiple sclerosis in the U.S.," Denise Bradley, a spokeswoman for Teva, said in an emailed statement. She said the company wants to "ensure that appropriate safeguards are implemented to maintain an acceptable risk-benefit profile."

Read at Reuters
Read at Pharmalot
Read at BusinessWeek
Read at Fox News

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES